https://www.selleckchem.com/products/LBH-589.html
Patients received a median of two red blood cell transfusions within the first 2weeks of diagnosis and a median of one AIHA-directed medication (range one to four), most commonly corticosteroids and rituximab. AIHA after HSCT is rare but occurs more commonly in patients transplanted for nonmalignant diagnoses. While some pediatric patients who develop AIHA after transplant can be managed on current immunosuppression and supportive care, many require AIHA-directed therapy including second-line medications. AIHA after HSCT is rare but occ
Like
Comment
Share
